Related Experiment Videos
Therapy of unstable angina with the low molecular weight heparins
1University of Insubria, Varese, Italy.
Insights
Low molecular weight heparins offer improved efficacy and safety for unstable angina management compared to unfractionated heparin. These agents provide therapeutic advantages with simpler administration and no need for routine monitoring.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Unstable angina often results from atherosclerotic plaque disruption and thrombus formation, necessitating prompt antithrombotic therapy.
- Aspirin and unfractionated heparin have been standard treatments, but low molecular weight heparins (LMWHs) offer enhanced properties.
Purpose of the Study:
- To evaluate the efficacy and safety of LMWHs in managing unstable angina.
- To compare LMWHs with unfractionated heparin in clinical trials.
Main Methods:
- Review of recent clinical trials assessing nadroparin, dalteparin, and enoxaparin in unstable angina patients.
- Comparison of pharmacokinetic, pharmacodynamic, efficacy, and safety profiles of LMWHs versus unfractionated heparin.
Main Results:
- LMWHs demonstrate comparable safety and effectiveness to unfractionated heparin in unstable angina.
- LMWHs offer significant therapeutic advantages, including simpler subcutaneous administration and fixed dosing without monitoring.
Conclusions:
- LMWHs represent a valuable therapeutic option for unstable angina, providing enhanced efficacy and safety.
- While generally comparable, subtle differences exist between LMWH agents and trial designs, requiring careful consideration.
Abstract:
Unstable angina is in most cases caused by partial or complete coronary artery occlusion due to the disruption of an atherosclerotic plaque and to thrombus formation. An immediate antithrombotic approach is essential to prevent fatal and non-fatal myocardial infarction, and the combination of aspirin and unfractionated heparin has played a pivotal role in the past years. Low molecular weight heparins have improved pharmacokinetic and pharmacodynamic properties over unfractionated heparin that have resulted in greater efficacy and safety in the field of venous thromboembolism. Low molecular weight heparins can be administered by once or twice daily subcutaneous injections at fixed, weight-adjusted doses without the need for monitoring. Because of their potential, many recent clinical trials have evaluated their efficacy and safety in the management of patients with unstable angina. Three low molecular weight heparins have so far been tested: nadroparin, dalteparin and enoxaparin. The results of the published trials confirm that the newer compounds are at least as safe and effective as unfractionated heparin, and offer considerable therapeutic advantages. Nevertheless, the different properties of the three compounds and perhaps the different designs of the clinical trials have led to not entirely comparable findings.